Conexeu Sciences (NASDAQ:CNXU) Shares Down 5.2% – Should You Sell?

Shares of Conexeu Sciences Inc. (NASDAQ:CNXU) traded down 5.2% on Thursday . The stock traded as low as $5.20 and last traded at $5.27. Approximately 304,950 shares were traded during trading, an increase of 15% from the average session volume of 264,938 shares. The stock had previously closed at $5.56.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Weiss Ratings began coverage on shares of Conexeu Sciences in a research report on Monday, August 17th. They set a “sell (e-)” rating for the company. Wall Street Zen upgraded shares of Conexeu Sciences to a “hold” rating in a report on Saturday, May 30th. Zacks Research raised shares of Conexeu Sciences to a “hold” rating in a research note on Monday, June 29th. Finally, HC Wainwright initiated coverage on shares of Conexeu Sciences in a report on Monday, June 22nd. They set a “buy” rating and a $20.00 price target for the company. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $20.00.

Conexeu Sciences Stock Down 5.7%

The firm has a market cap of $133.00 million and a price-to-earnings ratio of -45.18. The firm has a fifty day simple moving average of $8.70.

Conexeu Sciences (NASDAQ:CNXU) last issued its quarterly earnings data on Monday, June 15th. The company reported ($0.11) earnings per share (EPS) for the quarter. On average, sell-side analysts expect that Conexeu Sciences Inc. will post -0.4 earnings per share for the current year.

Insider Buying and Selling at Conexeu Sciences

In related news, Director Lynn Sebastian Purcell purchased 202,500 shares of Conexeu Sciences stock in a transaction dated Thursday, June 18th. The shares were acquired at an average cost of $0.80 per share, with a total value of $162,000.00. Following the purchase, the director owned 2,734,240 shares of the company’s stock, valued at approximately $2,187,392. The trade was a 8.00% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

About Conexeu Sciences

Conexeu is a company focused on building a new class of collagen-based regenerative tissue products. The Company was incorporated on November 2, 2022 under the Business Corporations Act (British Columbia) and was continued out of British Columbia and domesticated into the State of Nevada under the laws of the State of Nevada on April 10, 2025. — Conexeu is an early-stage medical device company formed to acquire and commercialize intellectual property (“IP”) developed over more than a decade at the University of British Columbia (the “University”) and the BC Professional Firefighters Burn and Wound Healing Laboratory.